CA2585523A1 - Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof - Google Patents

Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof Download PDF

Info

Publication number
CA2585523A1
CA2585523A1 CA002585523A CA2585523A CA2585523A1 CA 2585523 A1 CA2585523 A1 CA 2585523A1 CA 002585523 A CA002585523 A CA 002585523A CA 2585523 A CA2585523 A CA 2585523A CA 2585523 A1 CA2585523 A1 CA 2585523A1
Authority
CA
Canada
Prior art keywords
adenoviral
cells
replication
vector
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002585523A
Other languages
English (en)
French (fr)
Inventor
Daniele Catalucci
Stefano Colloca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2585523A1 publication Critical patent/CA2585523A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002585523A 2004-11-02 2005-10-27 Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof Abandoned CA2585523A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62445904P 2004-11-02 2004-11-02
US60/624,459 2004-11-02
PCT/EP2005/011629 WO2006048215A1 (en) 2004-11-02 2005-10-27 Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
CA2585523A1 true CA2585523A1 (en) 2006-05-11

Family

ID=35705355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002585523A Abandoned CA2585523A1 (en) 2004-11-02 2005-10-27 Adenoviral amplicon and producer cells for the production of replication-defective adenoviral vectors, methods of preparation and use thereof

Country Status (5)

Country Link
US (1) US20070298498A1 (enExample)
EP (1) EP1809753A1 (enExample)
JP (1) JP2008518591A (enExample)
CA (1) CA2585523A1 (enExample)
WO (1) WO2006048215A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111386126A (zh) * 2017-10-25 2020-07-07 Nouscom股份公司 真核细胞系
CN112206318A (zh) * 2020-03-16 2021-01-12 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的Ad7载体疫苗

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
CN102884196B (zh) * 2010-04-01 2015-05-06 肖卫东 重组病毒载体的结构及其制备
CN107466324B (zh) * 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
US20180161455A1 (en) * 2015-06-10 2018-06-14 American Gene Technologies International, Inc. Non-integrating viral delivery system and methods of use therof
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
CA3011529A1 (en) 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta t-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
KR101897499B1 (ko) 2016-06-14 2018-10-04 배재대학교 산학협력단 재조합 단백질 발현 증진을 위한 유전자 절편을 포함하는 발현 벡터
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
US12329793B2 (en) * 2019-03-20 2025-06-17 National University Corporation Hokkaido University Modified adenovirus and medicine comprising same
KR20220144416A (ko) 2020-02-04 2022-10-26 큐어백 아게 코로나바이러스 백신
US20230175011A1 (en) * 2020-03-28 2023-06-08 Greffex, Inc. Maintaining dna fragments in eukaryotic cells, approaches and uses
US20230210979A1 (en) * 2020-04-20 2023-07-06 Greffex, Inc. Engineering broadly reactive coronavirus vaccines and related designs and uses
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
CA3170741A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20240066114A1 (en) 2020-08-31 2024-02-29 CureVac SE Multivalent nucleic acid based coronavirus vaccines
CN120129693A (zh) 2022-08-01 2025-06-10 旗舰创业创新第七有限责任公司 免疫调节蛋白及相关方法
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 疫苗及相關方法
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
WO2025024486A2 (en) 2023-07-25 2025-01-30 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
CN117089577B (zh) * 2023-08-21 2024-06-25 暨南大学 重组的猴腺病毒、病毒载体及构建方法
WO2025128953A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025129034A2 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025129001A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
WO2025128943A1 (en) 2023-12-15 2025-06-19 Flagship Pioneering Innovations Vii, Llc Esterases and related methods
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752284B2 (en) * 1998-02-17 2002-09-12 Genzyme Corporation Methods for pseudoadenoviral vector production
JP4475561B2 (ja) * 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111386126A (zh) * 2017-10-25 2020-07-07 Nouscom股份公司 真核细胞系
CN111386126B (zh) * 2017-10-25 2024-01-30 Nouscom股份公司 真核细胞系
CN112206318A (zh) * 2020-03-16 2021-01-12 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的Ad7载体疫苗

Also Published As

Publication number Publication date
EP1809753A1 (en) 2007-07-25
JP2008518591A (ja) 2008-06-05
WO2006048215A1 (en) 2006-05-11
US20070298498A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
US20070298498A1 (en) Adenoviral Amplicon and Producer Cells for the Production of Replication-Defective Adenoviral Vectors, Methods of Preparation and Use Thereof
US12054737B2 (en) Potent and short promoter for expression of heterologous genes
AU2002218569B2 (en) Complementing cell lines
US8530234B2 (en) Hepatitis C virus vaccine
AU2002218569A1 (en) Complementing cell lines
AU2002337840A1 (en) Hepatitis C virus vaccine
Catalucci et al. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent ΔE1-E2-E3-E4 Ad5 vectors
EP2784155B1 (en) Adenovirus producing novel cell line and the use thereof
JP2008508899A (ja) アデノウイルスベクター組成物
JP4479973B2 (ja) Ｃ型肝炎ウイルスワクチン
CA2563396A1 (en) Method of using adenoviral vectors to induce an immune response
US7259009B2 (en) Self-rearranging DNA vectors
CZ402398A3 (cs) Molekuly DNA aplikující se in vivo, jejich příprava a farmaceutická kompozice, která je obsahuje
EP1127149B1 (en) Cells for the production of helper dependent adenoviral vectors
AU766771B2 (en) Packaging systems for human recombinant adenoviruses to be used in gene therapy
CA2463996A1 (en) Replication competent dual-ad vectors for vaccine and immunotherapy applications
EA045609B1 (ru) Высокоактивный и короткий промотор, предназначенный для экспрессии гетерологичных генов
Cultured Epstein-Barr Virus Hybrid− An Adenovirus

Legal Events

Date Code Title Description
FZDE Discontinued